Aurobindo Pharma , a leading pharmaceutical company, has announced the completion of an internal restructuring process involving its subsidiaries. The company has successfully transferred the ownership of CuraTeQ Biologics s.r.o. from one wholly owned subsidiary to another, streamlining its corporate structure.

Key Details of the Restructuring

• Transfer Completion: Aurobindo Pharma has finalized the transfer of shares of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to Curateq Biologics B.V.
• Timing: The share transfer was completed on September 30, 2025, ahead of the original November 30, 2025 deadline.
• Regulatory Approval: The transaction received confirmation from the local authorities in the Czech Republic on the same day.
• Ownership Change: As a result of this restructuring, CuraTeQ Biologics s.r.o. is now a wholly owned subsidiary of Curateq Biologics B.V., instead of Helix Healthcare B.V.

Background and Implications

The share transfer was part of a binding agreement entered into on July 29, 2025. This internal reorganization appears to be a strategic move by Aurobindo Pharma to optimize its corporate structure and potentially streamline operations within its biologics division.

Corporate Disclosure

In compliance with regulatory requirements, Aurobindo Pharma has promptly informed the stock exchanges about the completion of this transaction. The company's commitment to transparency is evident in its timely disclosures.

Additional Corporate Updates

In a separate announcement, Aurobindo Pharma also disclosed changes in its senior management. Mr. S. Venkatesh Kumar, Associate Vice President, has resigned from his position effective September 30, 2025. This change in the senior management team coincides with the completion of the subsidiary restructuring.

Aurobindo Pharma continues to adapt its corporate structure and management team, likely aiming to enhance operational efficiency and maintain its competitive edge in the pharmaceutical industry.

Aurobindo Pharma , a leading pharmaceutical company, has announced an extension to the timeline for transferring shares between its wholly-owned subsidiaries. The company has pushed back the deadline for the transfer of shares of CuraTeQ Biologics s.r.o. from Helix Healthcare B.V. to Curateq Biologics B.V.

Extended Timeline

The share transfer, which was originally scheduled to be completed by August 31, 2025, has now been extended to November 30, 2025. Aurobindo Pharma cited the pending receipt of an updated business register from Dutch authorities as the reason for this delay.

Background of the Agreement

A binding agreement for the transfer of entire shares was entered into on July 29, 2025. This agreement involves the restructuring of ownership between Aurobindo Pharma's wholly-owned subsidiaries.

Official Communication

In an official communication to the National Stock Exchange of India Limited and BSE Limited, B. Adi Reddy, Company Secretary of Aurobindo Pharma, stated, "Pending receipt of updated business register from authorities in The Netherlands reflecting the share transfer, the share transfer will be completed on or before November 30, 2025."

Additional Corporate Developments

In a separate update, Aurobindo Pharma also informed the stock exchanges about an extension in its plans to acquire a stake in a solar power company. The company has postponed its investment to acquire a 26% stake in Swarnaakshu Solar Power Private Limited. Originally planned for completion by September 30, 2025, this acquisition has now been extended to December 31, 2025, subject to receiving approval from the concerned state government for setting up a captive solar power plant.

Furthermore, Aurobindo Pharma has established a new wholly owned subsidiary named Curateq Biologics in Malta. This expansion of the company's corporate structure through a new entity in the European nation demonstrates Aurobindo Pharma's commitment to growth and international presence.

These updates reflect Aurobindo Pharma's ongoing efforts in corporate restructuring, diversification into renewable energy, and expansion of its global footprint, while also highlighting the regulatory processes involved in such transactions.